0.77
+0.0064(+0.83%)
Currency In USD
| Previous Close | 0.77 |
| Open | 0.76 |
| Day High | 0.8 |
| Day Low | 0.73 |
| 52-Week High | 2.11 |
| 52-Week Low | 0.39 |
| Volume | 21.56M |
| Average Volume | 3.86M |
| Market Cap | 225.57M |
| PE | -4.08 |
| EPS | -0.19 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.3 |
| Change | 0.01 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $1.16 as of December 21, 2024 at a share price of $0.774. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $1,985.38 as of December 21, 2024 at a share price of $0.774.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire Inc.
Dec 19, 2024 11:38 AM GMT
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculi
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
GlobeNewswire Inc.
Dec 11, 2024 12:02 PM GMT
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today annou
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
GlobeNewswire Inc.
Nov 27, 2024 12:09 PM GMT
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today annou